Last reviewed · How we verify
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
Details
| Lead sponsor | Prokidney |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 10 |
| Start date | Wed Apr 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Nov 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Type 2 Diabetes Mellitus
- Chronic Kidney Disease
Interventions
- Renal Autologous Cell Therapy (REACT)
Countries
United States